Potential reasons for resistance to RIT with cetuximab include EGFR mutants in the tyrosine kinase domain and oncogenes KRAS, NRAS, or BRAF, which can activate EGFR downstream signaling pathways even during EGFR inhibition, and the major tumor suppressor TP53 mutants. Here, BRAF is linked to neoplasm.